This project will enroll men with suspected recurrence of prostate cancer. This is to determine the correct localization rate of the investigational drug 18F-DCFPyL with PET/CT imaging in detection of recurrent prostate cancer. The secondary goal is to assess the impact of 18F-DCFPyL PET/CT disease detection, on patient’s clinical management plans.
This project was funded by: Sponsor funded
The term of this project was: April 2019 to December 2019
The number of subjects scanned during this project was: 10